

# **Certificate of Analysis for NR-51686**

### Candida glabrata, Strain DSY565

### Catalog No. NR-51686

### **Product Description:**

Candida glabrata (C. glabrata), strain DSY565 was isolated in 1995 from a patient with acquired immunodeficiency syndrome and oropharyngeal candidiasis following two courses of treatment with fluconazole. NR-51685 was produced by inoculation of the deposited material onto Yeast Mold agar, which was grown for 3 days at 25°C in an aerobic atmosphere. The agar growth was harvested with 20% glycerol to produce this lot.

Lot: 70027689 Manufacturing Date: 02AUG2019

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology <sup>1</sup>	Report results	Globose to subglobose; in singles and in clumps; no pseudohyphae observed
Colony morphology <sup>1</sup>	Report results	Butyrous, smooth and cream
Biochemical tests		
VITEK® 2 (YST card)	<i>C. glabrata</i> (≥ 89%)	C. glabrata (98%)
Antibiotic Susceptibility Profile		
Etest <sup>®</sup> antibiotic test strips <sup>2,3</sup>		
Amphotericin B	Report results	Susceptible (1.0 µg/mL) <sup>4</sup>
Fluconazole	Report results	Resistant (> 256 µg/mL)
Voriconazole	Report results	Resistant (8 µg/mL)
Genotypic Analysis		
Sequencing of partial 18S ribosomal RNA (rRNA) gene, internal transcribed spacer (ITS) 1, 5.8S rRNA gene, ITS 2, partial 26S rRNA (~ 840 base pairs) Sequencing of 28S rRNA gene (~ 600 base pairs)	≥ 99% sequence identity to  C. glabrata, strain DSY565 (GenBank: MVOF01000013.1) ≥ 99% sequence identity to  C. glabrata, strain DSY565 (GenBank: MVOE01000012.1)	100% sequence identity to <i>C. glabrata</i> , strain DSY565 (GenBank: MVOF01000013.1) <sup>5</sup> 100% sequence identity to <i>C. glabrata</i> , strain DSY565 (GenBank: MVOF01000013.1) <sup>5</sup>
Purity <sup>6</sup>		
Nutrient broth with 0.1% Yeast Extract at 25°C	No bacterial growth	No bacterial growth
Nutrient broth with 0.1% Yeast Extract at 37°C	No bacterial growth	No bacterial growth
Viability (post-freeze) <sup>7</sup>	Growth	Growth

<sup>&</sup>lt;sup>1</sup>4 days at 25°C in an aerobic atmosphere with 5% CO<sub>2</sub> on Yeast Mold agar

## /Heather Couch/

**Heather Couch** 06 APR 2021

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

**BEI Resources** 

E-mail: contact@beiresources.org www.beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

<sup>&</sup>lt;sup>2</sup>2 days at 37°C in an aerobic atmosphere on RPMI 1640 agar containing MOPS buffer and 2% glucose (Remel™ R04067)

<sup>&</sup>lt;sup>3</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: Song, Y. B., et al. "Antifungal Susceptibility Testing with Etest for Candida Species Isolated from Patients with Oral Candidiasis." Ann. Dermatol. 27 (2015): 715-720. PubMed: 26719641.

<sup>&</sup>lt;sup>4</sup>Two MICs were observed for amphotericin B (0.75 µg per mL and 1.0 µg per mL) under identical test conditions. The highest MIC is being reported as the test result.

<sup>&</sup>lt;sup>5</sup>Also consistent with *C. albicans* 

<sup>&</sup>lt;sup>6</sup>Clarity of broth was determined by visual inspection after 3 days in an aerobic atmosphere.

<sup>&</sup>lt;sup>7</sup>3 days at 25°C in an aerobic atmosphere on Yeast Mold agar